Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome

International Journal of Fertility and Women's Medicine

Volumn 47, Issue 5, 2002, Pages 211-226

  Delvigne, Annick ^a   Rozenberg, Serge ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Etiopathology; IVF; OHSS; RAS; Review article; VEGF

Indexed keywords

ANGIOGENIN; CYTOKINE; ENDOTHELIN; ESTROGEN; GONADOTROPIN; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; PROLACTIN; PRORENIN; PROSTAGLANDIN; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ARTICLE; CAPILLARY LEAK SYNDROME; FEMALE; HEMODYNAMICS; HUMAN; IATROGENIC DISEASE; INFLAMMATION; KALLIKREIN KININ SYSTEM; LUTEAL PHASE; OVARY DISEASE; OVULATION; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ARTERIOLES; CYTOKINES; E-SELECTIN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIN-1; ENZYME PRECURSORS; ESTROGENS; FEMALE; HISTAMINE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KALLIKREINS; KININS; LYMPHOKINES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PROLACTIN; PROSTAGLANDINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASODILATION; VON WILLEBRAND FACTOR;

EID: 0036757278     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. Rydberg E, Pedersen-Bjergaard K: Effect of serum gonadotrophin and chorionic gonadotrophin on the human ovary. J Am Med Assoc 121:1117-1122, 1943.
2. Davis E, Hellebaum AA: Observations on the experimental use of gonadotropic extracts in the human female. J Clin Endocrinol 4:400-409, 1944.
3. Bettendorf G, Lindner C: The ovarian hyperstimulation syndrome. Horm Metab Res 19(11):519-522, 1987.
4. Polishuk WZ, Schenker JG: Ovarian overstimulation syndrome. Fertil Steril 20(3):443-450, 1969.
5. Yarali H, Fleige-Zahradka BG, Yuen BH, et al: The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril 59(3):657-661, 1993.
6. Goldsman MP, Pedram A, Dominguez CE, et al: Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 63(2):268-272, 1995.
7. McClure N, Leya J, Radwanska E, et al: Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod 7(6):758-764, 1992.
8. Golan A, Ron-el R, Herman A, et al: Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 44(6):430-440, 1989.
9. Meirow D, Schenker JG, Rosler A: Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alpha-hydroxylase, 17,20-lyase deficiency: What is the role of oestrogens? Hum Reprod 11(10):2119-2121, 1996.
10. Wada I, Macnamee M, Brinsden P: Prevention and treatment of ovarian hyperstimulation. Hum Reprod 8(12):2245-2246, 1993.
11. Leung P, Ho Yuen B, Moon YS: Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 145(7):847-849, 1983.
12. Yuen BH, McComb P, Sy L, et al: Plasma prolactin, human chorionic gonadotrophin, estradiol, testosterone, and progesterone in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 133(3):316-320, 1979.
13. Schenker JG, Polishuk WZ: The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 6(2):47-52, 1976.
14. Schenker JG: Prevention and managements of ovarian hyperstimulation syndrome, in Genazzani AR, Petraglia F, Volpe A (eds): Progress in Gynecology and Obstetrics. Parthenon, pp 661-669, 1990.
15. Pride SM, Yuen BH, Moon YS, et al: Relationship of gonadotrophin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 154(5):1155-1160, 1986.
16. Borenstein R, Elhalah U, Lunenfeld B, et al: Severe ovarian hyperstimulation syndrome: A reevaluated therapeutic approach. Fertil Steril 51(5):791-795, 1989.
17. Fernandez LA, Caride VJ, Twickler J, et al: Renin-angiotensin and development of collateral circulation after renal ischemia. Am J Physiol 243(6):H869-H875, 1982.
18. Sherer DM, Eliakim R, Abulafia O: The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50(4):217-224, 2000.
19. Frederick JL, Shimanuki T, diZerega GS: Initiation of angiogenesis by human follicular fluid. Science 224(4647):389-390, 1984.
20. Derkx FH, Alberda AT, Zeilmaker GH, et al: High concentrations of immunoreactive renin, prorenin and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol 94(1):4-9, 1987.
21. Pellicer A, Palumbo A, DeCherney AH, et al: Blockage of ovulation by an angiotensin antagonist. Science 240(4859):1660-1661, 1988.
22. Loret de Mola JR, Goldfarb JM, Hecht BR, et al: Gonadotrophins induce higher active renin levels in the follicular fluid of normal and hyperstimulated cycles. Gynecol Endocrinol 13(3):155-160, 1999.
23. Fernandez LA, Tarlatzis BC, Rzasa PJ, et al: Renin-like activity in ovarian follicular fluid. Fertil Steril 44(2):219-223, 1985.
24. Navot D, Margalioth EJ, Laufer N, et al: Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48(1):57-61, 1987.
25. Haning RV, Jr, Strawn EY, Nolten WE: Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 66(2):220-224, 1985.
26. Moneta E, Marana R, Garcea N, et al: [Iatrogenic hyperstimulation of the ovary with ascites. Report of a case and considerations and management.] Acta Eur Fertil 8(2):155-166, 1977.
27. Ong AC, Eisen V, Rennie DP, et al: The pathogenesis of the ovarian hyperstimulation syndrome (OHS): A possible role for ovarian renin. Clin Endocrinol (Oxf) 34(1):43-49, 1991.
28. Delbaere A, Bergmann PJ, Gervy-Decoster C, et al: Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: Implications for pathophysiology and clinical management. Fertil Steril 62(4):731-737, 1994.
29. Delbaere A, Bergmann PJ, Gervy-Decoster C, et al: Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: Role of early pregnancy and ovarian gonadotrophin stimulation. Fertil Steril 67(6):1038-1045, 1997.
30. Delbaere A, Bergmann PJ, Englert Y: Features of the renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome. J Assist Reprod Genet 14(5):241-244, 1997.
31. Delbaere A, Bergmann PJ, Gervy-Decoster C, et al: Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome. Hum Reprod 12(2):236-240, 1997.
32. van de Vrie W, Baggen MG, Visser W, et al: High renin and prorenin in plasma and pleural exudate of a patient with the ovarian hyperstimulation syndrome. Neth J Med 51(6):232-236, 1997.
33. Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ: Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 10(6):1355-1358, 1995.
34. Teruel MJ, Carbonell LF, Teruel MG, et al: Effect of angiotensin-converting enzyme inhibitor on renal function in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 76(6):1232-1237, 2001.
35. Teruel MJ, Carbonell LF, Llanos MC, et al: Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 77(6):1256-1260, 2002.
36. Morris RS, Paulson RJ: Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril 71(3):562-563, 1999.
37. Morris RS, Miller C, Jacobs L, et al: Conservative management of ovarian hyperstimulation syndrome. J Reprod Med 40(10):711-714, 1995.
38. Balasch J, Arroyo V, Fabregues F, et al: Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Ann Intern Med 121(1):27-33, 1994.
39. Adashi EY: The potential relevance of cytokines to ovarian physiology: The emerging role of resident ovarian cells of the white blood cell series. Endocr Rev 11(3):454-464, 1990.
40. Motro B, Itin A, Sachs L, et al: Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87(8):3092-3096, 1990.
41. Simon C, Tsafriri A, Pellicer A, et al: The role of interleukins in the ovary. Reprod Med Rev 5:51-63, 1996.
42. Peterson CM, Hales HA, Hatasaka HH, et al: Interleukin-1 beta (IL-1 beta) modulates prostaglandin production and the natural IL-1 receptor antagonist inhibits ovulation in the optimally stimulated rat ovarian perfusion model. Endocrinology 133(5):2301-2306, 1993.
43. Friedlander MA, Loret de Mola JR, Goldfarb JM: Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril 60(5):826-833, 1993.
44. Loret de Mola JR, Flores JP, Baumgardner GP, et al: Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: Ovarian immunohistochemical localization of interleukin-6 signal. Obstet Gynecol 87(4):581-587, 1996.
45. Loret de Mola JR, Arredondo-Soberon F, Randle CP, et al: Markedly elevated cytokines in pleural effusion during the ovarian hyperstimulation syndrome: Transudate or ascites? Fertil Steril 67(4):780-782, 1997.
46. Orvieto R, Voliovitch I, Fishman P, et al: Interleukin-2 and ovarian hyperstimulation syndrome: A pilot study. Hum Reprod 10(1):24-27, 1995.
47. Oppenheim JJ, Ruscetti FW, Faltynek C: Cytokines, in Stites DP, Terr AI (eds): Basic and Clinical Immunology, 7th Ed. Appleton and Lange, East Norwalk, CT, p 78, 1991.
48. Delvigne A, Demoulin A, Smitz J, et al: The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. I. Clinical and biological features. Hum Reprod 8(9):1353-1360, 1993.
49. Delvigne A, Dubois M, Battheu B, et al: The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 8(9):1361-1366, 1993.
50. Wang LJ, Norman RJ: Concentrations of immunoreactive interleukin-1 and interleukin-2 in human preovulatory follicular fluid. Hum Reprod 7(2):147-150, 1992.
51. Revel A, Barak V, Lavy Y, et al: Characterization of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril 66(1):66-71, 1996.
52. Abramov Y, Schenker JG, Lewin A, et al: Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 11(7):1381-1386, 1996.
53. Chen CD, Wu MY, Chen HF, et al: Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril 72(2):286-292, 1999.
54. Chen CD, Wu MY, Chen HF, et al: Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod 15(1):66-71, 2000.
55. Geva E, Lessing JB, Lerner-Geva L, et al: Elevated levels of interleukin-6 in the follicular fluid at the time of oocyte retrieval for in vitro fertilization may predict the development of early-form ovarian hyperstimulation syndrome. Fertil Steril 68(1):133-137, 1997.
56. Pellicer A, Albert C, Mercader A, et al: The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71(3):482-489, 1999.
57. Toth P, Li X, Rao CV, et al: Expression of functional human chorionic gonadotrophin/human luteinizing hormone receptor gene in human uterine arteries. J Clin Endocrinol Metab 79(1):307-315, 1994.
58. Aboulghar MA, Mansour RT, Serour GI, et al: Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 87(1):81-85, 1999.
59. Artini PG, Monti M, Fasciani A, et al: Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 101(2):169-174, 2002.
60. Enskog A, Henriksson M, Unander M, et al: Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 71(5):808-814, 1999.
61. Enskog A, Nilsson L, Brannstrom M: Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotrophin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): Results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 96(2):196-201, 2001.
62. Manolopoulos K, Lang U, Gips H, et al: Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 99(2):226-231, 2001.
63. Orvieto R, Achiron A, Margalit R, et al: The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome. J Assist Reprod Genet 15(1):46-49, 1998.
64. Nakamura Y, Smith M, Krishna A, et al: Increased number of mast cells in the dominant follicle of the cow: Relationships among luteal, stromal, and hilar regions. Biol Reprod 37(3):546-549, 1987.
65. Knox GE: Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 118(7):992-994, 1974.
66. Knox GE, Dowd AJ, Spiesel SA, et al: Antihistamine blockade of the ovarian hyperstimulation syndrome. II. Possible role of antigen-antibody complexes in the pathogenesis of the syndrome. Fertil Steril 26(5):418-421, 1975.
67. Erlik Y, Naot Y, Friedman M, et al: Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol 53(5):580-582, 1979.
68. Pride J, Ho YI: The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol 8:247-253, 1990.
69. Ferrara N, Houck KA, Jakeman LB, et al: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47(3):211-218, 1991.
70. Einspanier R, Schonfelder M, Muller K, et al: Expression of the vascular endothelial growth factor and its receptors and effects of VEGF during in vitro maturation of bovine cumulus-oocyte complexes (COC). Mol Reprod Dev 62(1):29-36, 2002.
71. Yan Z, Weich HA, Bernart W, et al: Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 77(6):1723-1725, 1993.
72. Yamamoto S, Konishi I, Tsuruta Y, et al: Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 11(6):371-381, 1997.
73. Krasnow JS, Berga SL, Guzick DS, et al: Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil Steril 65(3):552-555, 1996.
74. Christenson LK, Stouffer RL: Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotrophin stimulation of vascular endothelial growth factor production by macaque granulosa cells from preand periovulatory follicles. J Clin Endocrinol Metab 82(7):2135-2142, 1997.
75. Lee A, Christenson LK, Stouffer RL, et al: Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil Steril 68(2):305-311, 1997.
76. Neulen J, Raczek S, Pogorzelski M, et al: Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod 4(3):203-206, 1998.
77. Neulen J, Yan Z, Raczek S, et al: Human chorionic gonadotrophin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80(6):1967-1971, 1995.
78. Van Blerkom J, Antczak M, Schrader R: The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: Association with vascular endothelial growth factor levels and perifollicular blood flow characteristics. Hum Reprod 12(5):1047-1055, 1997.
79. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985, 1983.
80. McClure N, Healy DL, Rogers PA, et al: Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344(8917):235-236, 1994.
81. Abramov Y, Barak V, Nisman B, et al: Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 67(2):261-265, 1997.
82. Agrawal R, Conway G, Sladkevicius P, et al: Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 70(4):651-658, 1998.
83. Agrawal R, Tan SL, Wild S, et al: Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71(2):287-293, 1999.
84. Ludwig M, Jelkmann W, Bauer O, et al: Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 14(10):2437-2441, 1999.
85. Kamat BR, Brown LF, Manseau EJ, et al: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 146(1):157-165, 1995.
86. Artini PG, Fasciani A, Monti M, et al: Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 70(3):560-564, 1998.
87. Levin ER, Rosen GF, Cassidenti DL, et al: Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 102(11):1978-1985, 1998.
88. Geva E, Amit A, Lessing JB, et al: Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? J Reprod Med 44(2):91-96, 1999.
89. D'Ambrogio G, Fasciani A, Monti M, et al: Serum vascular endothelial growth factor levels before starting gonadotrophin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome. Gynecol Endocrinol 13(5):311-315, 1999.
90. Neulen J, et al: [VEGF in the follicular fluid] 2001.
91. Aboulghar MA, Mansour RT, Serour GI, et al: Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Hum Reprod 13(8):2068-2071, 1998.
92. Ujioka T, Matsuura K, Tanaka N, et al: Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: Studies in a rat model. Hum Reprod 13(11):3009-3015, 1998.
93. Daniel Y, et al: [VCAM, ICAM] 1999.
94. Abramov Y, Schenker JG, Lewin A, et al: Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Fertil Steril 75(1):51-57, 1002.
95. Daniel Y, Geva E, Amit A, et al: Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. Am J Reprod Immunol 45(3):154-160, 2001.
96. Brock TA, Dvorak HF, Senger DR: Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138(1):213-221, 1991.
97. Ogawa S, Minakami H, Araki S, et al: A rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. J Assist Reprod Genet 18(2):114-119, 2001.
98. Todorow S, Schricker ST, Siebzehnruebl ER, et al: Von Willebrand factor: An endothelial marker to monitor invitro fertilization patients with ovarian hyperstimulation syndrome. Hum Reprod 8(12):2039-2046, 1993.
99. Elchalal U, Schenker JG: The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas. Hum Reprod 12(6):1129-1137, 1997.
100. Kamada S, Kubota T, Taguchi M, et al: High levels of immunoreactive endothelin-1 in human follicular fluids. Hum Reprod 8(5):674-677, 1993.
101. Balasch J, Arroyo V, Fabregues F, et al: Immunoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertil Steril 64(1):65-68, 1995.
102. Beerendonk, et al: [Endothelin 1] 2001.
103. Akerman FM, Lei Z, Rao CV, et al: A case of spontaneous ovarian hyperstimulation syndrome with a potential mutation in the HCG/LH receptor gene. Fertil Steril 74(2):403-404, 2000.
104. Delvigne A, Vandromme J, Demeestere I, et al: Unpredictable cases of complicated ovarian hyperstimulation in IVF. Int J Fertil 42(4):268-270, 1997.
105. Evbuomwan IO, Davison JM, Baylis PH, et al: Altered osmotic thresholds for arginine vasopressin secretion and thirst during superovulation and in the ovarian hyperstimulation syndrome (OHSS): Relevance to the pathophysiology of OHSS. Fertil Steril 75(5):933-941, 2001.
106. Balasch J, Fabregues F, Arroyo V: Peripheral arterial vasodilation hypothesis: A new insight into the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 13(10):2718-2730, 1998.